Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Loved by Experts & Customers Trusted by skincare professionals worldwide
Side Effects & Mitigation Because there is no completed human safety trial, the honest statement is that the human side-effect profile is not well characterised
Trx: thioredoxin
It should only be handled within qualified laboratory environments.
CJC-1295 (NO DAC) + Ipamorelin Blend Peptide Pharmacokinetics & Metabolism Absorption & Distribution The CJC-1295 (NO DAC) + Ipamorelin blend peptide exhibits distinct pharmacokinetic profiles for each component when administered in research settings: CJC-1295 (NO DAC): Subcutaneous administration results in gradual absorption with peak plasma concentrations within 1-4 hours Half-life of approximately 30 minutes to 2 hours enables pulsatile growth hormone stimulation Distribution throughout systemic circulation with selective binding to pituitary GHRH receptors Bioavailability significantly improved compared to native GHRH due to enhanced enzymatic resistance Ipamorelin: Rapid absorption following subcutaneous administration with peak levels at approximately 40 minutes Terminal half-life of approximately 2 hours in human pharmacokinetic studies Dose-proportional pharmacokinetic parameters across studied dose ranges Volume of distribution at steady-state of 0.22 L/kg indicating limited tissue distribution When administered together, ipamorelin provides rapid-onset growth hormone pulse generation (peak at 0.67 hours) while CJC-1295 maintains elevated baseline growth hormone levels through sustained GHRH receptor activation
US$ 28.63
US$ 23.27
US$ 24.93
